Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 12Neoplasms 3Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Adenocarcinoma 1

Interventions

Gemcitabine 4Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3PEGPH20 2napabucasin 1folfirinox 1Radiotherapy 1Enoxaparin 1Dexamethasone 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Pancreatic Ductal × folfirinox × Clear all
NCT02243007 2017-05-16

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Terminated
7 enrolled 8 charts
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡